Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiotoxicity with vascular endothelial growth factor inhibitor therapy
Rhian M. Touyz, Joerg Herrmann
npj Precision Oncology (2018) Vol. 2, Iss. 1
Open Access | Times Cited: 171

Showing 1-25 of 171 citing articles:

Targeted drug delivery strategies for precision medicines
Mandana T. Manzari, Yosi Shamay, Hiroto Kiguchi, et al.
Nature Reviews Materials (2021) Vol. 6, Iss. 4, pp. 351-370
Open Access | Times Cited: 712
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio‐Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio‐Oncology Society
Alexander R. Lyon, Susan Dent, Susannah Stanway, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 11, pp. 1945-1960
Open Access | Times Cited: 543
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Joerg Herrmann
Nature Reviews Cardiology (2020) Vol. 17, Iss. 8, pp. 474-502
Open Access | Times Cited: 517
Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio‐Oncology Council of the European Society of Cardiology (ESC)
Jelena Čelutkienė, Radek Pudil, Teresa López‐Fernández, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 9, pp. 1504-1524
Open Access | Times Cited: 306
Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management
Sunitha Shyam Sunder, Umesh C. Sharma, Saraswati Pokharel
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 187
VEGF-A in Cardiomyocytes and Heart Diseases
Mariantonia Braile, Simone Marcella, Leonardo Cristinziano, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 15, pp. 5294-5294
Open Access | Times Cited: 185
The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy
Nicolas Ricard, Sabine Bailly, Christophe Guignabert, et al.
Nature Reviews Cardiology (2021) Vol. 18, Iss. 8, pp. 565-580
Open Access | Times Cited: 168
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031
Jessica A. Pollard, Todd A. Alonzo, Robert B. Gerbing, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 18, pp. 2023-2035
Open Access | Times Cited: 77
The Role of Biomarkers in Cardio-Oncology
Kajaluxy Ananthan, Alexander R. Lyon
Journal of Cardiovascular Translational Research (2020) Vol. 13, Iss. 3, pp. 431-450
Open Access | Times Cited: 133
Lead bioactive compounds of Aloe vera as potential anticancer agent
Ranabir Majumder, Chandan Kanta Das, Mahitosh Mandal
Pharmacological Research (2019) Vol. 148, pp. 104416-104416
Closed Access | Times Cited: 79
The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets
Siarhei A. Dabravolski, Victoria A. Khotina, Andrey V. Omelchenko, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 931-931
Open Access | Times Cited: 67
Etiology and management of hypertension in patients with cancer
Turab Mohammed, Meghana Singh, John Glenn Tiu, et al.
Cardio-Oncology (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 59
Anti-angiogenesis in cancer therapeutics: the magic bullet
Ayodipupo Sikiru Oguntade, Faez Al-Amodi, Abdullah Alrumayh, et al.
Journal of the Egyptian National Cancer Institute (2021) Vol. 33, Iss. 1
Open Access | Times Cited: 56
VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications
Nicholas D. Camarda, Richard Travers, Vicky K. Yang, et al.
Current Oncology Reports (2022) Vol. 24, Iss. 4, pp. 463-474
Open Access | Times Cited: 51
Understanding Sorafenib-Induced Cardiovascular Toxicity: Mechanisms and Treatment Implications
Jue Li, Lusha Zhang, Teng Ge, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 829-843
Open Access | Times Cited: 11
Multi-lineage heart-chip models drug cardiotoxicity and enhances maturation of human stem cell-derived cardiovascular cells
Maedeh Mozneb, Amelia Jenkins, Samuel Sances, et al.
Lab on a Chip (2024) Vol. 24, Iss. 4, pp. 869-881
Closed Access | Times Cited: 9
Vascular Endothelial Growth Factor Receptors in the Vascularization of Pancreatic Tumors: Implications for Prognosis and Therapy
C.J. Grobbelaar, Vanessa Steenkamp, Peace Mabeta
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 3, pp. 179-179
Open Access | Times Cited: 1
Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer
Kalyan R. Chitturi, Jiaqiong Xu, Raquel Araujo‐Gutierrez, et al.
JACC CardioOncology (2019) Vol. 1, Iss. 2, pp. 182-192
Open Access | Times Cited: 72
Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure
Sarah Waliany, Daniel Lee, Ronald Witteles, et al.
The Annual Review of Pharmacology and Toxicology (2020) Vol. 61, Iss. 1, pp. 113-134
Open Access | Times Cited: 61
Endothelial ERK1/2 signaling maintains integrity of the quiescent endothelium
Nicolas Ricard, Rizaldy P. Scott, Carmen J. Booth, et al.
The Journal of Experimental Medicine (2019) Vol. 216, Iss. 8, pp. 1874-1890
Open Access | Times Cited: 58
Cardiovascular Toxicity Induced by Kinase Inhibitors: Mechanisms and Preclinical Approaches
Sarah D. Lamore, Rebecca Kohnken, Matthew F. Peters, et al.
Chemical Research in Toxicology (2019) Vol. 33, Iss. 1, pp. 125-136
Open Access | Times Cited: 57
Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine
Antonio Matrone, Carla Gambale, Alessandro Prete, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 33
Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology
Zehua Liang, Yuquan He, Xin Hu
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10617-10617
Open Access | Times Cited: 32
Cardiovascular Toxicity Induced by Vascular Endothelial Growth Factor Inhibitors
Diana Mihalcea, Hayat Memis, S. Mihaila, et al.
Life (2023) Vol. 13, Iss. 2, pp. 366-366
Open Access | Times Cited: 17
Immune Checkpoint Inhibitor–Induced Cardiotoxicity
Dorte Nielsen, Carsten Bogh Juhl, Ole Haagen Nielsen, et al.
JAMA Oncology (2024) Vol. 10, Iss. 10, pp. 1390-1390
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top